

COVID-19 VACCINES:  
US AND INTERNATIONAL ROLL-OUT



In our last update, we discussed US-wide and global vaccine roll-out as well as the updated studies regarding both the **Pfizer** and **Moderna** vaccines. In this update, we wanted to touch on how that roll-out has been proceeding both throughout the United States as well as globally and update on the AstraZeneca vaccine through its US Emergency Use Authorization process.



Authorized/Approved Vaccines				
Name	Vaccine Type	Primary Developers	Country of Origin	Country of Authorization / Approval
mRNA-1273	mRNA-based vaccine	Moderna	US	US
BNT162b2	mRNA-based vaccine	Pfizer, BioNTech; Fosun Pharma	Multi-national	UK, Bahrain, Canada, Mexico, US, Singapore, Oman, Saudi Arabia, Kuwait
Ad26.COV2.S	Adenovirus vaccine	Johnson & Johnson	US	US, France, Canada, Germany, Italy
AZD1222	Adenovirus vaccine	AstraZeneca	UK	UK, Bahrain, Brazil, EU, India, South Africa
CoronoVac	Inactivated vaccine (formalin with alum adjuvant)	Sinovac	China	China, Brazil, Chile, Turkey
No name announced	Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	China	China
Sputnik V	Non-replicating viral vector	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Russia	Russia
BBIBP-CorV	Inactivated vaccine	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	China	China, United Arab Emirates, Bahrain
Convidicea (Ad5-nCoV)	Recombinant vaccine (adenovirus type 5 vector)	CanSino Biologics	China	Mexico, China (military use), Pakistan
Covaxin	Inactivated vaccine	Bharat Biotech, ICMR	India	India
EpiVacCorona	Peptide Vaccine	Federal Budgetary Research Institute State Research Center of Russia Virology and Biotechnology	Russia	Russia

Over the last week, we have heard the encouraging results that AstraZeneca announced regarding its COVID-19 vaccine. Apparently, those results may have been based on outdated and incomplete information about the vaccine’s effectiveness. The National Institute of Allergy and Infectious Diseases stated that an independent panel of medical experts that has been helping oversee AstraZeneca’s US trial had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” This sort of conflict is highly irregular and will most likely trigger extra scrutiny of the AstraZeneca vaccine by the FDA and other regulators.

The largest vaccination campaign of all time is currently underway. More than 468 million doses have been administered across 135 countries. In the United States, more Americans have received at least one dose than have tested positive for the virus since the pandemic started. More Americans have now received at least one dose than

**Vaccines Across America**


Across the U.S., enough doses have been administered to cover 19.7% of the population, and 78% of the delivered shots have been used



have tested positive for the virus since the pandemic started. With the current vaccination rate of approximately 2.5 million doses per day, it will take an estimated total of 5 months to cover 75% of the US population.


It is interesting to note, as of this week, almost 20% of the population has received at least one dose and with certain states like Ohio lowering the age requirement to 16 on 03/29, that number is set to increase significantly. New Mexico leads all states, with enough vaccinations to cover 26.6% of its population.

Internationally, Israel has shown that vaccines are having a strong effect. The country has led the



world in vaccination percentage and by the end of February had more than 85% of the 70+ population covered with 2 doses. Severe COVID cases and deaths declined significantly due to this. The United States still leads for total number of doses administered with 128M. China is second with almost 75M administered and the

EU, India and the UK follow. The vaccine rollout is occurred more quickly in developed countries, leading to questions regarding allotment per country. This leads us to believe that although the US should reach 75% sometime over the summer, the world may take significantly longer (years) to get to the same level.



Written by: Ram Vellanki, MD, MBA  
Investment Banking Associate  
**Lawrence, Evans & Co., LLC**  
*Investment Banking, Healthcare Finance, Consulting*  
88 E. Broad St, Suite 1750  
Columbus, OH 43215  
Phone 614.448.1304  
rvellanki@lawrenceevans.com  
www.lawrenceevans.com



Lawrence, Evans & Co., LLC. is a boutique healthcare financial advisory and investment banking firm comprised of senior level professionals who provide lead advisory services to private companies, lenders, and other parties-in-interest that are executing financial and strategic transactions. Founded in 2003, the firm provides a wide array of services such as finance and capital raising, mergers and acquisitions, management consultancy services, turnaround management and restructuring, and real estate finance and development. The firm caters to the healthcare providers and service companies (senior housing, hospital, physician services, dental, dermatology, ophthalmology, physical therapy, behavioral health, RCM, HCIT, Population Health, etc.), transportation and logistics, and business services. Transactions are typically under \$250 million or \$10 million EBITDA.

<b>INVESTMENT BANKING &amp; CORPORATE FINANCE</b>	<ul style="list-style-type: none"> <li>• Private Company Sales</li> <li>• Division/Subsidiary Divestitures</li> <li>• Distressed Transaction Advisory</li> </ul>	<ul style="list-style-type: none"> <li>• Acquisition Advisory Services</li> <li>• Private Market Financings</li> <li>• LBO's and Recapitalizations</li> </ul>
<b>CONSULTING</b>	<ul style="list-style-type: none"> <li>• Strategic Options Analysis</li> <li>• Valuations &amp; Financial Assessments</li> <li>• Interim CEO/CFO</li> </ul>	<ul style="list-style-type: none"> <li>• Strategic Planning</li> <li>• Organizational Reviews</li> <li>• Expert Testimony &amp; Opinions</li> </ul>
<b>TURNAROUND &amp; RESTRUCTURING</b>	<ul style="list-style-type: none"> <li>• Turnaround Management</li> <li>• Debt Restructuring/Refinancing</li> <li>• Orderly Liquidations</li> </ul>	<ul style="list-style-type: none"> <li>• Chief Restructuring Officer (CRO)</li> <li>• Bankruptcy Planning / 363 Sales</li> <li>• Receivership / Trustee</li> </ul>

## Represented Healthcare Transactions

<p>SKILLED NURSING &amp; ASSISTED LIVING PORTFOLIO</p> <p>\$35,000,000 MULTI-FACILITY REFINANCING</p> <p> ACTED AS ADVISOR</p>	<p> GROWTH CAPITAL RAISE</p> <p> STRATEGIC ROYALTY CORP</p> <p> ACTED AS ADVISOR</p>	<p> GROWTH CAPITAL RAISE</p> <p>\$1,000,000</p> <p> ACTED AS ADVISOR AND INVESTOR</p>	<p> Discover, Simplify, Perform</p> <p>PURCHASED</p> <p>MULTI SPECIALTY MEDICAL BILLING COMPANY</p> <p> ACTED AS ADVISOR</p>
<p> Problem Solved</p> <p>SALE TO</p> <p> Unique Healthcare IT Company .com</p> <p> ACTED AS ADVISOR</p>	<p>NON-RECOURSE HOTEL CONSTRUCTION LOAN</p> <p>175 ROOM HYATT HOUSE</p> <p>\$18,026,000</p> <p> ACTED AS ADVISOR</p>	<p>MEDICAL BILLING AND TECHNOLOGY COMPANY</p> <p>\$8,000,000</p> <p>SALE TO A STRATEGIC BUYER</p> <p> ACTED AS ADVISOR</p>	<p> Optimizing Performance &amp; Profit For Healthcare Professionals</p> <p>SALE TO A STRATEGIC BUYER</p> <p> ACTED AS ADVISOR</p>

Neil Johnson  
Managing Director  
njohnson@lawrenceevans.com

Ram Vellanki, MD, MBA  
Associate  
rvellanki@lawrenceevans.com

